Google AI

Weekend Times


The Times

PR Newswire

Clarity Pharmaceuticals closes $25m capital raising-PR Newswire APAC

  • Written by: PR Newswire Asia - The Times Au RSS

SYDNEY, Dec. 15, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of $25,000,410.

Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals, commented, "It has been a pivotal year for Clarity with numerous critical milestones achieved in the development of our main products, advancement of our platform, as well as accelerated corporate and strategic activities despite facing an unprecedented global environment.

"The money raised will enable us to keep the momentum from 2020 going and provide financial resources to progress the following important initiatives:

- SARTATE

  • Progress the Cu-64/Cu-67 SARTATE Neuroblastoma trial at the Memorial Sloan Kettering Cancer Center in children with neuroblastoma;
  • Expand the Cu-64/Cu-67 SARTATE Neuroblastoma trial to additional clinical sites across the US with the ultimate goal of developing better treatment options for children with cancer; and
  • Commence patient recruitment in Phase II Cu-64 SARTATE Neuroendocrine trial.

- SAR-Bombesin

  • Progress and expand the Cu-64 BOmbesin in Breast CAncer Trial (C-BOBCAT) led by A/Prof Louise Emmett, Director of Theranostics and Nuclear Medicine, at St Vincent's Hospital in Sydney with an aim of developing better treatment options to women with metastatic breast cancer, an area currently with a high unmet need;
  • Expand the C-BOBCAT trial to include prostate cancer patients; and
  • Seek US Food and Drug Administration's (FDA) approval for an Investigational New Drug (IND) Application.

- SAR-bisPSMA

  • Commence a clinical trial in the US for Cu-64/Cu-67 SAR-bisPSMA (theranostic) and in Australia for Cu-64 SAR-bisPSMA (diagnostic) to build on the promising pre-clinical data with the help of an internationally recognised team of key opinion leaders in the prostate cancer field; and
  • Seek US FDA approval for an IND Application.

- Develop new targeted theranostic products for a broad range of cancer types, utilising Clarity's SAR Technology Platform and the Cu-64/Cu-67 pairing."

Dr Taylor continued, "Clarity has a strong focus on getting its lead product SARTATE to market, supported by the US FDA granting both Cu-67 SARTATE and Cu-64 SARTATE Orphan Drug Designations and Rare Paediatric Disease Designations for the treatment and clinical management of neuroblastoma, as well as developing the copper platform in large and unmet clinical indications."

"It has been a very exciting year for Clarity" Dr Taylor added. "We would like to sincerely thank our long-term shareholders for their continued support of Clarity, as well as welcome and thank a broad range of new shareholders including institutions, family offices, high net-worth individuals and others who wanted to be part of the Clarity story. We would also like to thank Blue Ocean Equities for their contribution in assisting us with the capital raise."

About Clarity

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies based on it's SAR Technology Platform for the treatment of cancer and other serious diseases in adults and children.

www.claritypharmaceuticals.com[1]  

 

View original content:http://www.prnewswire.com/news-releases/clarity-pharmaceuticals-closes-25m-capital-raising-301192496.html[2]

Read more https://www.prnasia.com/story/archive/3223996_CN23996_0

The Weekend Times Magazine

How To Install PVC Shutters At Home

Homes are the best place for relaxing and refreshing after the hectic and tiring daily life routine. The home should be decorated so that it gives people a warm welcome...

Out of 500 Nominations, My Guardian Breaks into Top 3 at Australia’s Prestigious 2025 ACE Awards

Sydney, 22 July 2025 – From humble beginnings to national recognition, My Guardian is celebrating a milestone achievement - being selected as one of the top three finalists in the...

Last Call for Tradies Before Christmas

The Christmas bells might not be ringing for Santa yet, but they are fast approaching, and the sooner you start getting organised, the better. Before you start present shopping or...

The Ultimate Guide to Choosing the Right Removalists for Your Next Move

Whether you are relocating for work, upgrading your living space, or downsizing, the process of moving often requires careful planning, organization, and assistance. One of the most important steps in...

Aussie Rules Football History

One of the things that make Australia truly unique is its own version of football. Called Australia rules football, this sport precedes other contemporary football games in generating an official...

Why Choosing The Right Sleep Apnea Mask Can Improve Your Daily Life

Sleep is the body’s reset button, but for individuals dealing with interrupted breathing, nights can feel restless and incomplete. This is where a sleep apnea mask becomes an essential part of...

Turning fashion into power - Beauty with Brains

During this unfortunate time of our lives there’s a hidden gem business which keeps the hopes up for many lives of women of all walks of life. Fashion...

Let's talk about nits!

My daughter struggled with nits for 8 years until I found this miracle cure Nits. The one-word granted to strike fear into mums everywhere … and have them immediately scratching their...

Diamonds & Why They Are The Popular Choice For Any Occasion Here In Australia

Diamonds have been an incredibly popular gem for many years now and they continue to be so even now in 2024. It seems like the perfect jewel to choose for...

hacklink esim new zealandBetimgrandpashabet girişzlibraryz libraryjojobetcialis 20 mg fiyat